Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

S100A9 And EGFR Gene Signatures Predict Disease Progression In Muscle Invasive Bladder Cancer Patients After Chemotherapy.

W. Kim, J. Kim, C. Yan, P. Jeong, S. Y. Choi, O. J. Lee, Y. B. Chae, S. J. Yun, S. C. Lee, W. E. Kim
Published 2014 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND In our previous gene expression profile analysis, IL1B, S100A8, S100A9, and EGFR were shown to be important mediators of muscle invasive bladder cancer (MIBC) progression. The aim of the present study was to investigate the ability of these gene signatures to predict disease progression after chemotherapy in patients with locally recurrent or metastatic MIBC. PATIENTS AND METHODS Patients with locally advanced MIBC who received chemotherapy were enrolled. The expression signatures of four genes were measured and carried out further functional analysis to confirm our findings. RESULTS Two of the four genes, S100A9 and EGFR, were determined to significantly influence disease progression (P = 0.023, 0.045, respectively). Based on a receiver operating characteristic curve, a cut-off value for disease progression was determined. Patients with the good-prognostic signature group had a significantly longer time to progression and cancer-specific survival time than those with the poor-prognostic signature group (P < 0.001, 0.042, respectively). In the multivariate Cox regression analysis, gene signature was the only factor that significantly influenced disease progression [hazard ratio: 4.726, confidence interval: 1.623-13.763, P = 0.004]. In immunohistochemical analysis, S100A9 and EGFR positivity were associated with disease progression after chemotherapy. Protein expression of S100A9/EGFR showed modest correlation with gene expression of S100A9/EGFR (r = 0.395, P = 0.014 and r = 0.453, P = 0.004). Our functional analysis provided the evidence demonstrating that expression of S100A9 and EGFR closely associated chemoresistance, and that inhibition of S100A9 and EGFR may sensitize bladder tumor cells to the cisplatin-based chemotherapy. CONCLUSIONS The S100A9/EGFR level is a novel prognostic marker to predict the chemoresponsiveness of patients with locally recurrent or metastatic MIBC.
This paper references
10.1002/1097-0142(20011215)92:12<2985::AID-CNCR10175>3.0.CO;2-5
Preoperative plasma levels of transforming growth factor β1 strongly predict clinical outcome in patients with bladder carcinoma
S. Shariat (2001)
10.1097/01.JU.0000162039.38023.5F
Update on chemotherapy for advanced bladder cancer.
J. Rosenberg (2005)
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase (2005)
Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer.
S. Shariat (2003)
New Haven; 6 Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital
10.1016/j.cell.2012.04.042
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Swarnali Acharyya (2012)
10.1016/S0090-4295(02)02253-7
C: IGF-I l IGFBP-3 l ☆
S. Shariat (2003)
10.1016/S1040-8428(03)00067-2
Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
J. Bellmunt (2003)
10.1093/ANNONC/MDL435
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
J. Bellmunt (2007)
10.1056/NEJMOA032520
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.
I. Lossos (2004)
10.1136/BMJ.312.7038.1079
Statistics notes: Transformations, means, and confidence intervals
J. Bland (1996)
10.1016/S0022-5347(05)65348-7
Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer.
B. Andrews (2002)
10.1002/(SICI)1522-2683(19990101)20:4/5<1047::AID-ELPS1047>3.0.CO;2-E
The analysis of S100A9 and S100A8 expression in matched sets of macroscopically normal colon mucosa and colorectal carcinoma: The S100A9 and S100A8 positive cells underlie and invade tumor mass
J. Štulík (1999)
10.1200/JCO.1997.15.7.2564
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
S. Saxman (1997)
10.1093/OXFORDJOURNALS.ANNONC.A059105
The treatment of advanced bladder cancer.
C. Sternberg (1995)
10.1021/pr2008187
Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer.
W. S. Yang (2012)
10.1007/BF02977781
Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells
H. Yong (2007)
10.1200/JCO.2008.18.5744
Generation of a concise gene panel for outcome prediction in urinary bladder cancer.
A. P. Mitra (2009)
10.2119/molmed.2010.00274
A Four-Gene Signature Predicts Disease Progression in Muscle Invasive Bladder Cancer
W. Kim (2011)
10.1016/J.YEXCR.2005.10.013
S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.
Alexander Hermani (2006)
10.1016/S0022-5347(05)00370-8
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
H. von der Maase (2005)
10.1056/NEJMOA041588
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
S. Paik (2004)
10.1038/ncb1206-1321
S100 chemokines mediate bookmarking of premetastatic niches
S. Rafii (2006)
10.1200/JCO.2007.25.18_SUPPL.5055
A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy
D. Bajorin (2007)
10.1016/S0959-8049(01)00231-3
EGFR and cancer prognosis.
R. Nicholson (2001)



This paper is referenced by
Inflammatory Cells and Mediators in the Tumor Microenvironment of Breast Cancer
Roni Allaoui (2017)
s 100 a 9 regulates cisplatin chemosensitivity of squamous cervical cancer cells and related mechanism
Chuchu Zhao (2018)
10.18632/oncotarget.24229
Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance
M. Lee (2018)
10.7150/thno.25130
Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism
Austin Yeon (2018)
10.1007/s10577-015-9471-y
Canine urothelial carcinoma: genomically aberrant and comparatively relevant
S. Shapiro (2015)
10.4049/jimmunol.1402771
Tumor-Associated and Disease-Associated Autoantibody Repertoires in Healthy Colostrum and Maternal and Newborn Cord Sera
A. Madi (2015)
10.1517/13543784.2015.1070483
An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer
Y. C. Lee (2015)
10.1016/j.canlet.2018.08.014
Integrated proteomic and phosphoproteomic analyses of cisplatin-sensitive and resistant bladder cancer cells reveal CDK2 network as a key therapeutic target.
J. H. Jung (2018)
10.1016/j.critrevonc.2015.05.005
Emerging concepts on drug resistance in bladder cancer: Implications for future strategies.
F. Massari (2015)
10.1186/s12917-017-1032-5
Diagnostic performance of the urinary canine calgranulins in dogs with lower urinary or urogenital tract carcinoma
R. Heilmann (2017)
Chromatin alterations during transformation of B cells by a constitutively active mutant of STAT5
Samy Unser (2019)
10.3892/or.2015.3807
Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Zejun Yan (2015)
10.1177/0022034518756330
Calprotectin and the Initiation and Progression of Head and Neck Cancer
P. Argyris (2018)
10.1080/15321819.2016.1146757
Prognostic value of immunohistochemical expression profile of epidermal growth factor receptor in urothelial bladder cancer
A. Arfaoui (2016)
10.1007/s11684-016-0469-4
Regulatory mechanism and functional analysis of S100A9 in acute promyelocytic leukemia cells
Y. Zhu (2017)
10.1016/j.bbalip.2018.06.005
Glucose-derived acetate and ACSS2 as key players in cisplatin resistance in bladder cancer.
H. Wen (2019)
10.1158/1078-0432.CCR-15-1169
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder
Wei-Jan Wang (2016)
10.2147/CMAR.S168276
S100A9 regulates cisplatin chemosensitivity of squamous cervical cancer cells and related mechanism
Chuchu Zhao (2018)
10.1158/1940-6207.CAPR-14-0251
Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
C. Michailidi (2015)
10.21037/TAU.2020.03.13
Tumor heterogeneity in muscle-invasive bladder cancer
H. Kang (2020)
10.4081/oncol.2016.320
Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention
Amrallah A. Mohammed (2016)
10.1007/s11864-014-0319-z
The Role of Genomics in the Management of Advanced Bladder Cancer
E. Guancial (2015)
10.1016/j.currproblcancer.2014.06.001
Multimodal management of muscle-invasive bladder cancer.
J. C. Park (2014)
10.7150/ijbs.45640
S-Palmitoylation as a Functional Regulator of Proteins Associated with Cisplatin Resistance in Bladder Cancer
Muhammad Shahid (2020)
10.1007/s11523-015-0357-x
The route to personalized medicine in bladder cancer: where do we stand?
F. Massari (2015)
Inhibition of the EGFR / STAT 3 / CEBPD axis reverses cisplatin cross-resistance with paclitaxel in the urothelial carcinoma of the urinary bladder
Wei-Jan Wang (2016)
10.7150/jca.28409
Elevated Serum S100A9 Indicated Poor Prognosis in Hepatocellular Carcinoma after Curative Resection
J. Meng (2019)
10.3390/molecules24030581
Elucidation of the Mechanism of Action for Metal Based Anticancer Drugs by Mass Spectrometry-Based Quantitative Proteomics
Shuailong Jia (2019)
10.1111/cas.13143
Carbonic anhydrase 2 is a novel invasion‐associated factor in urinary bladder cancers
Hirokazu Tachibana (2017)
10.1093/annonc/mdu113
Gene expression and prognosis in bladder cancer--real progress? Editorial on 'S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy'.
J. Symanowski (2014)
10.18632/oncotarget.10539
Establishment and antitumor effects of dasatinib and PKI-587 in BD-138T, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant EGFR amplification and PTEN deletion
Nakho Chang (2016)
10.1186/s12964-020-00625-7
Role of tyrosine kinases in bladder cancer progression: an overview
Amir Sadra Zangouei (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar